Biograph 2 pet ct

All PET/CT scans were performed using a Siemens Biograph PET/CT system in three cooperating nuclear medicine units (Siemens Biograph 2 PET/CT; Siemens Biograph Sensation 16 PET/CT; Siemens Biograph 64 True Point).
¹⁸F-2-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) was used as a tracer in all patients. Blood glucose levels were measured before performing the scan, and the examination was conducted only in patients with a glucose level <150 mL/dL.
After injecting 300–382 MBq ¹⁸F-FDG during the distribution phase, the patients were placed in a resting position to avoid any muscular activity. The PET/CT scan was performed 60–90 min after tracer injection. The CT scan was performed as a low-dose multi-slice CT with 2, 16, or 64 slices. The entire examination was conducted according to current guidelines.

Prior to PRRT, all patients underwent SSTR-PET/CT according to EANM guidelines to assess tumor receptor expression [11 (link)]. A median of 124 Megabecquerel (MBq) (range, 61-239 MBq) of ⁶⁸Ga-DOTATATE/-TOC was injected intravenously. After 60 minutes, imaging was performed using the following devices: Bonn, Biograph 2 PET/CT (Siemens Medical Solutions, Erlangen, Germany); Wuerzburg, Biograph 64 (Siemens Medical Solutions, Erlangen, Germany); Munich, Gemini TF PET/CT (Philips Medical, Eindhoven, Netherlands) or Siemens Biograph 64 (Siemens Medical Solutions, Erlangen, Germany); Hannover, Biograph 2 (Siemens Medical Solutions, Erlangen, Germany). All data was reconstructed using iterative algorithms implemented by the manufacturer and depending on the routine protocol of the different medical centers. Scatter and attenuation correction was performed based on the different transmission data.